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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not the
use of omega-3 polyunsaturated fatty acids (PUFA) as adjunctive therapy is effective in reducing
symptom severity in adult schizophrenia patients.
STUDY DESIGN: A selective review of three peer-reviewed, double-blind, randomized,
placebo-controlled trials published between the years of 2008 and 2016.
DATA SOURCES: All three randomized control trials were published in English and were
selected from peer-reviewed journals via EmBase and PubMed based on relevance to the clinical
question posed above and that the outcomes measured in the studies mattered to patients, or were
“patient oriented.”
OUTCOMES MEASURED: Outcomes of changes in schizophrenia symptom severity were
measured by comparing Positive and Negative Symptom Scale (PANSS) scores before and after
treatment with either antipsychotic plus placebo or antipsychotic plus omega-3 PUFA.
RESULTS: Studies performed by Manteghiy, et. al. and Bentsen, et. al. revealed no statistically
significant improvements in PANSS scores before and after treatment with antipsychotic plus
omega-3 PUFA. The study performed by Pawelczyk, et. al. revealed statistically significant
improvement in PANSS scores before and after treatment with antipsychotic plus omega-3
PUFA.
CONCLUSIONS: Based on the selective review of the studies included in this paper, evidence
is still unclear as to whether or not the use of omega-3 PUFAs as adjunctive therapy is effective
in reducing symptom severity in adult schizophrenia patients. Further research into the topic
must be conducted in order to gather more evidence, as only a limited number of clinical trials all
with small sample sizes observed over a short time frame have been performed throughout the
last 10 years.
KEY WORDS: omega-3 fatty acids, schizophrenia
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INTRODUCTION
Schizophrenia is the most common psychotic illness diagnosed in the U.S., affecting 7 in
1000 people throughout their lifetime.1 Although this may seem like a modest prevalence, being
familiar with the treatment available for schizophrenia is relevant to all fields of medicine and
providers throughout all specialties, since about 50-90% of people with mental illness additionally
need treatment for one or more chronic medical illnesses.1 The estimated cost of treating patients
with schizophrenia in the U.S. was estimated to total $155.7 billion in 2013. This includes not only
direct healthcare costs but also societal costs such as caregiving and unemployment.2 Throughout
2009-2011, schizophrenia is estimated to have produced 382,000 emergency department visits
yearly in the U.S., which includes adults aged 18-64; this totals to about 20.1 visits per every
10,000 adults in the U.S.3 Thus, it is evident that this disease affects not only the healthcare system,
but society as a whole.
Schizophrenia is a chronic psychiatric illness with onset in early adulthood. The disease
has periods of inactivity through its course as well as periods of active disease defined by episodes
of psychosis. When a patient is actively going through psychosis, this period is characterized by
the patient’s inability to distinguish between reality and unreality. The psychotic symptoms of
schizophrenia are categorized into “positive” and “negative” symptoms. Positive symptoms
include hallucinations, delusions, and bizarre behavior. Negative symptoms include flat affect,
anhedonia, apathy, and decrease speech.4
The exact cause of schizophrenia remains unknown. However, since antipsychotic
medication, the staple of maintenance treatment in schizophrenia, affects dopamine and serotonin
receptors in the brain, it is known that these are the main neurotransmitters involved in the
mechanism of action and process of the disease. Both first-generation, or “typical”, antipsychotics
and second-generation, or “atypical”, antipsychotics are prescribed to patients with schizophrenia
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as maintenance therapy in order to reduce the frequency and severity at which patients experience
psychotic symptoms. Typical antipsychotics include chlorpromazine, perphenazine, and
haloperidol while atypical antipsychotics include clozapine, risperidone, olanzapine, quetiapine,
ziprasidone, and aripiprazole.1
While the negative symptoms of this disease are arguably the most debilitating,
antipsychotic medications are only proven to target the improvement of positive symptoms of
psychosis through their chemical mechanism of action. Arguably, many claim that by controlling
the frequency and severity of positive symptoms, antipsychotics simultaneously aid in decreasing
the severity of negative symptoms, as well. However, evidence-based research on pharmacologic
treatment directly targeting the reduction in severity of negative symptoms still remains elusive,
as does a cure for the disease.
The treatment options discussed above are all crucial in maintenance treatment of
schizophrenia, but the elusive nature of a cure requires research into alternative, adjunctive
treatment. It is important to assess the efficacy of the use of alternative medicine in symptom
improvement, especially since many antipsychotics have intolerable side effects. Omega-3
polyunsaturated fatty acids (PUFAs) have been found to be one alternative medicine option to
have positive effects on patients with schizophrenia. Research into this option of adjunctive
therapy has been ongoing since the 1980s, when it was discovered that omega-3 fatty acid
concentrations were low in schizophrenia patients. The thought behind providing supplementation
of these compounds to patients is that they promote cellular wall formation, which decreases
neuronal destruction and in turn the active symptomatology of this chronic disease.5 This paper
goes on to evaluate three double-blind, randomized, placebo-controlled trials comparing the
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efficacy of omega-3 PUFAs as adjunctive therapy in reducing symptom severity for adults with
schizophrenia.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not the use of
omega-3 polyunsaturated fatty acids (PUFAs) as adjunctive therapy is effective in reducing
symptom severity in adult schizophrenia patients.
METHODS
Three double-blind, randomized, placebo-controlled trials were chosen for review. The
patient population selected for review included patients over the age of 18 years old presenting
with first-episode schizophrenia. The interventions whose efficacy were assessed included omega3 PUFAs as adjunctive treatment for patients that were also prescribed antipsychotic therapy. The
results of control groups receiving antipsychotic therapy in conjunction with a placebo were
compared to results of experimental groups receiving antipsychotic therapy in conjunction with
omega-3 PUFAs. For purposes of this paper, outcomes measured focused on the reduction of
symptom severity in adult schizophrenia patients as measured by the patients’ Positive and
Negative Symptom Scale (PANSS) scores before and after treatment.
All articles being reviewed were selected from peer-reviewed journals via EmBase and
PubMed based on relevance to the clinical question posed above and that the outcomes measured
in the studies mattered to patients, or were “patient oriented.” The three studies were all published
in English between the years of 2008 and 2016. Keywords used to research the topic were “omega3 fatty acids” and “schizophrenia”. Inclusion criteria for the studies selected were that they were
double-blind, randomized, placebo-controlled trials published after the year 2008. Exclusion
criteria included studies focused on patients under the age of 18 years old previously diagnosed
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with schizophrenia being treated solely with antipsychotics. Detailed inclusion and exclusion
criteria as well as demographics of patient populations of each individual study are outlined in
Table 1 below. The statistics reported in the studies and utilized for review include p-values.
Table 1 – Demographics & Characteristics of Included Studies
Study
Type #
Age
Inclusion
Exclusion
pts
(years)
Criteria
Criteria
5
Manteghiy RCT 85 Active
Diagnosis of
Use of depot
(2008)
treatment schizophrenia
antipsychotic
= 37.38 ± confirmed by 2 medication;
6.2
psychiatrists
substance
using DSM-4
dependency;
Placebo
criteria
medical
= 39.03 ±
illness during
7.12
2 weeks prior
to start of
study
Bentsen6
RCT 97 18-39
Schizophrenia, Substance
(2013)
schizodependence;
affective
allergy to trial
disorder, or
agents;
schizocurrent
phreniform
warfarin use;
disorder;
indicators of
admitted to a
impaired
Norwegian
hemostasis
psychiatric
department
within the last
21 days and
prescribed
antipsychotics
7
Pawełczyk RCT 71 16-35
Aged 16-35
> 2 years
(2016)
and diagnosed since positive
with firstsymptom
episode
onset; use of
schizophrenia
anticoagulant;
according to
omega-3 fatty
the ICD-10
acid within 8
weeks; mania,
drug-induced
psychosis,
organic
disorders, or

W/D

Interventions

0

Active
treatment:
yellow pearls
of 2000 mg
fish oil, 360
mg EPA, and
240 mg DHA
vs. placebo
similar in
appearance
Active
treatment: 2
capsules
twice a day
of 500 mg
EPA plus 2
capsules
twice a day
of 500 mg
paraffin oil
Placebo: 4
capsules
twice a day
of 500 mg
paraffin oil
Active
treatment: 4
yellow gel
capsules
containing
0.33 g of
EPA and
0.22 g of
DHA each
Placebo: 4
yellow gel
capsules

24

5
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intellectual
disability;
unstable
medical
condition

filled with
olive oil

OUTCOMES MEASURED
The primary outcomes measured for purposes of this selective EBM review were the
reduction of symptom severity in adult schizophrenia patients as measured by changes in Positive
and Negative Symptoms Severity (PANSS) scores before and after treatment with either
antipsychotic in conjunction with placebo (control group) or antipsychotic in conjunction with
omega-3 PUFA (experimental group). Total PANSS scores used for purposes of comparison were
calculated by the researcher by averaging the PANSS scores in each study that fell under the
categories

of

“positive

symptoms”,

“negative

symptoms”,

and

“general/general

psychopathology”. The PANSS scores from the beginning of each study and the end of each study
were compared, and the mean change from baseline as well as the percent change in baseline
between control and experimental groups was compared to evaluate efficacy of the interventions
in reference to the p-values indicated in each study.
RESULTS
Manteghiy, et. al. conducted a randomized control trial on 85 subjects: 42 subjects received
the antipsychotic risperidone 2-8 mg by mouth in one daily dose in conjunction with an omega-3
PUFA which came in the form of a yellow pearl consisting of 2000 mg fish oil, 360 mg EPA, and
240 mg DHA while 43 subjects received the same antipsychotic but with a placebo pill similar in
appearance to the omega-3 PUFA.5 Patient demographics as well as inclusion and exclusion
criteria were similar for each group, and are detailed in Table 1 above. Both groups received the
assigned interventions daily, and PANSS scores were recorded at weeks 0, 3, and 6.

Goenaga, Omega-3 PUFAs and Schizophrenia 6
Table 2 – PANSS Scores in Placebo and Omega-3 PUFA Groups5
Week 0 Week 6
Mean
Change
from
Baseline
48.927 38.890
-10.037
Risperidone + placebo
-11.376
Risperidone + Omega-3 PUFA 49.833 38.457

%
Change
from
Baseline
20.514
22.828

p-value

0.001
0.002

Comparison of the percent changes from baseline between the placebo and experimental
groups depicted in Table 2 above revealed no statistically significant changes in PANSS scores
from week 0 to week 6 of the study, as the researchers of this study defined a p-value greater than
0.1 as statistically significant. This indicates that although 2.314% more subjects receiving
risperidone in conjunction with the omega-3 PUFA reported improvement in their PANSS scores
after treatment, this outcome is more likely attributed to chance and is therefore not reliable in
assessing the true efficacy of the interventions.
Bentsen, et. al. conducted a randomized control trial on 104 subjects aged 18-39 years old
in which they assessed the efficacy of antipsychotic in conjunction with placebo omega-3 PUFA
and placebo vitamins versus antipsychotic in conjunction with placebo omega-3 PUFA and active
vitamins, antipsychotic in conjunction with active omega-3 PUFA and placebo vitamins, or
antipsychotic in conjunction with active omega-3 PUFA and active vitamins.6 However, for the
purposes of this paper, the outcomes of only 58 subjects were assessed: the control group consisted
of 25 subjects receiving antipsychotic in conjunction with placebo omega-3 PUFA and placebo
vitamins while the experimental group consisted of 33 subjects receiving antipsychotic in
conjunction with active omega-3 PUFA and placebo vitamins. The antipsychotics varied among
patients, as they were prescribed at the choice of the researching therapist. The control group
received their prescribed antipsychotic along with four capsules twice a day of 500 mg of paraffin
oil. The experimental group received their prescribed antipsychotic along with two capsules twice
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a day of 500 mg of active EPA and two capsules twice a day of 500 mg of paraffin oil. Patient
demographics as well as inclusion and exclusion criteria were similar for each group, and are
detailed in Table 1 above. Both groups received the assigned interventions daily, and PANSS
scores were recorded at weeks 0, 4, 8, and 16.
Table 3 – PANSS Scores in Placebo and Omega-3 PUFA Groups6
Week Week
Mean
0
16
Change from
Baseline
Antipsychotic + placebo
Antipsychotic + Omega-3 PUFA

80.8
80.8

58.7
68.8

-22.1
-12.0

%
Change
from
Baseline
27.351
14.851

p-value

0.0001
0.248

Comparison of the percent changes from baseline between the placebo and experimental
groups depicted in Table 3 above revealed no statistically significant changes in PANSS scores
from week 0 to week 16 of the study in the experimental group, as the researchers of this study
defined a p-value less than 0.05 as statistically significant. However, the changes in PANSS scores
for the control group were found to be statistically significant. This indicates that the changes in
the experimental group were likely attributed to chance and are therefore not reliable in assessing
the true efficacy of the interventions. Further, 12.5% more subjects receiving antipsychotic in
conjunction with placebo reported improvement in their PANSS scores after treatment, which also
shows that this study did not show any positive relationship between the addition of omega-3
PUFAs in the treatment regimen of patients with schizophrenia and improvement in PANSS
scores.
Pawelczyk, et. al. conducted a randomized control trial on 71 subjects aged 16-35 years
old. The antipsychotics varied among patients, as they were prescribed and titrated according to
the Polish standards of pharmacotherapy of mental disorders; however, all antipsychotics were
dosed similarly by converting their doses into chlorpromazine equivalents. 36 patients in the
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experimental group received antipsychotic in conjunction with four yellow gel capsules containing
0.33 g of EPA and 0.22 g of DHA each while 35 patients in the placebo group received
antipsychotic in conjunction with four yellow gel capsules filled with olive oil.7 Patient
demographics as well as inclusion and exclusion criteria were similar for each group, and are
detailed in Table 1 above. Both groups received the assigned interventions daily, and PANSS
scores were recorded at weeks 0, 2, 4, 6, 8, and 26.
Table 4 – PANSS Scores in Placebo and Omega-3 PUFA Groups7
Week Week
Mean
0
26
Change
from
Baseline
96.80 82.38
-14.42
Chlorpromazine + placebo
98.40 79.13
-19.27
Chlorpromazine + Omega-3 PUFA

%
Change
from
Baseline
14.90
19.58

p-value

0.016
0.017

Comparison of the percent changes from baseline between the placebo and experimental
groups depicted in Table 4 above revealed statistically significant changes in PANSS scores from
week 0 to week 26 of the study in the experimental group, as the researchers of this study defined
a p-value less than 0.05 as statistically significant. This indicates that the changes in the
experimental group are reliable in assessing the true efficacy of the interventions. Further, 4.68%
more subjects receiving chlorpromazine-equivalent antipsychotic in conjunction with omega-3
PUFA reported improvement in their PANSS scores after treatment, which also shows that this
study did find evidence in support of a positive relationship between the addition of omega-3
PUFAs in the treatment regimen of patients with schizophrenia and improvement in PANSS
scores.
Although all patients in these studies were being treated with antipsychotics, which have
marked adverse reactions including extrapyramidal symptoms (EPS), tardive dyskinesia, diarrhea,
constipation, weight changes, and changes in libido, the articles do not comment much further on
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how many subjects in their trials experienced these reactions. This was controlled by tracking
compliance in every subject throughout the entire duration of all studies. Further, more
commentary on the adverse reactions was not necessary, as the outcomes being measured focused
on omega-3 PUFA supplementation, which has no known or documented serious adverse reactions
in comparison to the antipsychotics.
DISCUSSION
There were several limitations to the studies selected for review that must be discussed in
order to gain a better understanding of the scope and limitation of the results derived from the
research for this paper.
First, the study conducted by Bentsen, et. al. included patients with diagnoses of psychotic
disorders that were not only limited to schizophrenia, such as schizoaffective disorder and
schizophreniform disorder. Since the other studies focused on patients with the sole diagnosis of
schizophrenia, this could have greatly skewed the results explained in this paper. Further, although
both studies by Manteghiy, et. al. and Pawelczyk, et. al. focused only on patients with a diagnosis
of schizophrenia, the definitions that were utilized varied. Manteghiy, et. al. defined schizophrenia
according to DSM-4 criteria while Pawelczyk, et. al. utilized the definition of schizophrenia as
outlined in ICD-10. The definitions are clearly similar, as the disease process remains the same,
but these minor details should have been taken into account and controlled in order to have results
that are more readily available for direct comparison.
Further, it must be addressed that although the question for this paper focuses on “adult
schizophrenia patients,” the population for the study performed by Pawelczyk, et. al. included
subjects aged 16-35 years old. The study does not go into detail outlining how many subjects were
under the age of 18, which would be important to note for purposes of this review since the
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population specified in the clinical question being posed specifies “adult” patients, which includes
those over the age of 18 years old. The question also does not specify whether or not the patients
being studied and treated are being managed in an inpatient setting or outpatient setting. Studies
performed by Manteghiy, et. al. and Pawelczyk, et. al. focused on patients admitted to psychiatric
departments in various hospitals for the first time that had never received treatment with
antipsychotics before. On the other hand, Bentsen, et. al. focused on patients admitted to a
psychiatric department in various hospitals for the first time within the past 21 days; thus, these
patients could have been receiving a regimen of antipsychotics for longer than in the other studies.
Lastly, all of the studies reviewed had small sample sizes and were conducted over
relatively short periods of time. Adjusting these factors would provide more evidence to further
look into the true efficacy of omega-3 PUFAs as adjunctive treatment in adult schizophrenia
patients.
CONCLUSIONS
Overall, the results of the studies in this systematic review provide no conclusive evidence
as to whether or not the use of omega-3 PUFAs as adjunctive therapy is effective in reducing
symptom severity in adult schizophrenia patients. Secondary to the limitations of each study and
variables that are difficult to control, most namely the definitions of schizophrenia utilized for all
subjects across all studies and the inclusion of patients with other psychotic disorders, it can be
concluded that the current evidence provided on the topic is very limited. Therefore, further
studies with inclusion criteria that is more specific as well as studies that observe subjects through
longer periods of time may be necessary to gain a better understanding of the role of omega-3
PUFAs, a very benign supplement with no serious known side effects, in the treatment of
schizophrenia, a disease that affects millions.
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